|
1
|
Selby NM and Taal MW: An updated overview
of diabetic nephropathy: Diagnosis, prognosis, treatment goals and
latest guidelines. Diabetes Obes Metab. 22(Suppl 1): S3–S15. 2020.
View Article : Google Scholar
|
|
2
|
Ashfaq A, Meineck M, Pautz A, Arioglu-Inan
E, Weinmann-Menke J and Michel MC: A systematic review on renal
effects of SGLT2 inhibitors in rodent models of diabetic
nephropathy. Pharmacol Ther. 249:1085032023. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Luk AO, Li X, Zhang Y, Guo X, Jia W, Li W,
Weng J, Yang W, Chan WB, Ozaki R, et al: Quality of care in
patients with diabetic kidney disease in Asia: The Joint Asia
diabetes evaluation (JADE) registry. Diabet Med. 33:1230–1239.
2016. View Article : Google Scholar
|
|
4
|
Bays H: From victim to ally: The kidney as
an emerging target for the treatment of diabetes mellitus. Curr Med
Res Opin. 25:671–681. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Anders HJ, Davis JM and Thurau K: Nephron
protection in diabetic kidney disease. N Engl J Med. 375:2096–2098.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shimizu M, Suzuki K, Kato K, Jojima T,
Iijima T, Murohisa T, Iijima M, Takekawa H, Usui I, Hiraishi H and
Aso Y: Evaluation of the effects of dapagliflozin, a sodium-glucose
co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using
transient elastography in patients with type 2 diabetes and
non-alcoholic fatty liver disease. Diabetes Obes Metab. 21:285–292.
2019. View Article : Google Scholar
|
|
7
|
Diaz-Cruz C, Gonzalez-Ortiz M,
Rosales-Rivera LY, Patino-Laguna AJ, Ramirez-Rodriguez ZG,
Diaz-Cruz K and Martínez-Abundis E: Effects of dapagliflozin on
blood pressure variability in patients with prediabetes and
prehypertension without pharmacological treatment: A randomized
trial. Blood Press Monit. 25:346–350. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Xin Y, Guo Y, Li Y, Ma Y, Li L and Jiang
H: Effects of sodium glucose cotransporter-2 inhibitors on serum
uric acid in type 2 diabetes mellitus: A systematic review with an
indirect comparison meta-analysis. Saudi J Biol Sci. 26:421–446.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jhund PS, Ponikowski P, Docherty KF,
Gasparyan SB, Bohm M, Chiang CE, Desai AS, Howlett J, Kitakaze M,
Petrie MC, et al: Dapagliflozin and recurrent heart failure
hospitalizations in heart failure with reduced ejection fraction:
An analysis of DAPA-HF. Circulation. 143:1962–1972. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
McMurray JJV, Wheeler DC, Stefansson BV,
Jongs N, Postmus D, Correa-Rotter R, Chertow GM, Greene T, Held C,
Hou FF, et al: Effect of dapagliflozin on clinical outcomes in
patients with chronic kidney disease, with and without
cardiovascular disease. Circulation. 143:438–448. 2021. View Article : Google Scholar
|
|
11
|
Wiviott SD, Raz I, Bonaca MP, Mosenzon O,
Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, et
al: Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N
Engl J Med. 380:347–357. 2019. View Article : Google Scholar
|
|
12
|
Heerspink HJL, Stefansson BV, Chertow GM,
Correa-Rotter R, Greene T, Hou FF, Lindberg M, McMurray J, Rossing
P, Toto R, et al: Rationale and protocol of the dapagliflozin and
prevention of adverse outcomes in chronic kidney disease (DAPA-CKD)
randomized controlled trial. Nephrol Dial Transplant. 35:274–282.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Quagliariello V, De Laurentiis M, Rea D,
Barbieri A, Monti MG, Carbone A, Paccone A, Altucci L, Conte M,
Canale ML, et al: The SGLT-2 inhibitor empagliflozin improves
myocardial strain, reduces cardiac fibrosis and pro-inflammatory
cytokines in non-diabetic mice treated with doxorubicin. Cardiovasc
Diabetol. 20:1502021. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dixon SJ, Lemberg KM, Lamprecht MR, Skouta
R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS,
et al: Ferroptosis: An iron-dependent form of nonapoptotic cell
death. Cell. 149:1060–1072. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yang XD and Yang YY: Ferroptosis as a
novel therapeutic target for diabetes and its complications. Front
Endocrinol (Lausanne). 13:8538222022. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Stockwell BR: Ferroptosis turns 10:
Emerging mechanisms, physiological functions, and therapeutic
applications. Cell. 185:2401–2421. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kajarabille N and Latunde-Dada GO:
Programmed Cell-death by ferroptosis: Antioxidants as mitigators.
Int J Mol Sci. 20:49682019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ayala A, Munoz MF and Arguelles S: Lipid
peroxidation: Production, metabolism, and signaling mechanisms of
malondialdehyde and 4-hydroxy-2-nonenal. Oxid Med Cell Longev.
2014:3604382014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li S, Zheng L, Zhang J, Liu X and Wu Z:
Inhibition of ferroptosis by up-regulating Nrf2 delayed the
progression of diabetic nephropathy. Free Radic Biol Med.
162:435–449. 2021. View Article : Google Scholar
|
|
20
|
Lee H, Zandkarimi F, Zhang Y, Meena JK,
Kim J, Zhuang L, Tyagi S, Ma L, Westbrook TF, Steinberg GR, et al:
Energy-stress-mediated AMPK activation inhibits ferroptosis. Nat
Cell Biol. 22:225–234. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Muller T, Dewitz C, Schmitz J, Schroder
AS, Brasen JH, Stockwell BR, Murphy JM, Kunzendorf U and Krautwald
S: Necroptosis and ferroptosis are alternative cell death pathways
that operate in acute kidney failure. Cell Mol Life Sci.
74:3631–3645. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang Y, Bi R, Quan F, Cao Q, Lin Y, Yue C,
Cui X, Yang H, Gao X and Zhang D: Ferroptosis involves in renal
tubular cell death in diabetic nephropathy. Eur J Pharmacol.
888:1735742020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang L, Zhang J, Jin Y, Yao G, Zhao H,
Qiao P and Wu S: Nrf2 is a potential modulator for orchestrating
iron homeostasis and redox balance in cancer cells. Front Cell Dev
Biol. 9:7281722021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Parfenova H, Basuroy S, Bhattacharya S,
Tcheranova D, Qu Y, Regan RF and Leffler CW: Glutamate induces
oxidative stress and apoptosis in cerebral vascular endothelial
cells: Contributions of HO-1 and HO-2 to cytoprotection. Am J
Physiol Cell Physiol. 290:C1399–C1410. 2006. View Article : Google Scholar
|
|
25
|
Garcia-Nino WR and Pedraza-Chaverri J:
Protective effect of curcumin against heavy metals-induced liver
damage. Food Chem Toxicol. 69:182–201. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lu C, Xu W, Zhang F, Shao J and Zheng S:
Nrf2 knockdown disrupts the protective effect of curcumin on
Alcohol-induced hepatocyte necroptosis. Mol Pharm. 13:4043–4053.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lu C, Zhang F, Xu W, Wu X, Lian N, Jin H,
Chen Q, Chen L, Shao J, Wu L, et al: Curcumin attenuates
ethanol-induced hepatic steatosis through modulating Nrf2/FXR
signaling in hepatocytes. IUBMB Life. 67:645–658. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Han L, Li L and Wu G: Induction of
ferroptosis by carnosic acid-mediated inactivation of Nrf2/HO-1
potentiates cisplatin responsiveness in OSCC cells. Mol Cell
Probes. 64:1018212022. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hu Q, Zuo T, Deng L, Chen S, Yu W, Liu S,
Liu J, Wang X, Fan X and Dong Z: β-Caryophyllene suppresses
ferroptosis induced by cerebral ischemia reperfusion via activation
of the NRF2/HO-1 signaling pathway in MCAO/R rats. Phytomedicine.
102:1541122022. View Article : Google Scholar
|
|
30
|
Yang W, Wang Y, Zhang C, Huang Y, Yu J,
Shi L, Zhang P, Yin Y, Li R and Tao K: Maresin1 protect against
ferroptosis-induced liver injury through ROS inhibition and
Nrf2/HO-1/GPX4 activation. Front Pharmacol. 13:8656892022.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gong F, Ge T, Liu J, Xiao J, Wu X, Wang H,
Zhu Y, Xia D and Hu B: Trehalose inhibits ferroptosis via NRF2/HO-1
pathway and promotes functional recovery in mice with spinal cord
injury. Aging (Albany NY). 14:3216–3232. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yang J, Mo J, Dai J, Ye C, Cen W, Zheng X,
Jiang L and Ye L: Cetuximab promotes RSL3-induced ferroptosis by
suppressing the Nrf2/HO-1 signalling pathway in KRAS mutant
colorectal cancer. Cell Death Dis. 12:10792021. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Huang B, Wen W and Ye S: Dapagliflozin
ameliorates renal tubular ferroptosis in diabetes via SLC40A1
stabilization. Oxid Med Cell Longev. 2022:97355552022. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhang Z, Li L, Dai Y, Lian Y, Song H, Dai
X, Su R, Yin J and Gu R: Dapagliflozin inhibits ferroptosis and
ameliorates renal fibrosis in diabetic C57BL/6J mice. Sci Rep.
15:71172025. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
36
|
Stockwell BR, Friedmann Angeli JP, Bayir
H, Bush AI, Conrad M, Dixon SJ, Fulda S, Gascón S, Hatzios SK,
Kagan VE, et al: Ferroptosis: A regulated cell death nexus linking
metabolism, redox biology, and disease. Cell. 171:273–285. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tiwari BK, Pandey KB, Abidi AB and Rizvi
SI: Markers of oxidative stress during diabetes mellitus. J
Biomark. 2013:3787902013.PubMed/NCBI
|
|
38
|
Bruni A, Pepper AR, Pawlick RL, Gala-Lopez
B, Gamble AF, Kin T, Seeberger K, Korbutt GS, Bornstein SR,
Linkermann A and Shapiro AMJ: Ferroptosis-inducing agents
compromise in vitro human islet viability and function. Cell Death
Dis. 9:5952018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Dekkers CCJ, Wheeler DC, Sjostrom CD,
Stefansson BV, Cain V and Heerspink HJL: Effects of the
sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients
with type 2 diabetes and Stages 3b-4 chronic kidney disease.
Nephrol Dial Transplant. 33:2005–2011. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yao D, Wang S, Wang M and Lu W:
Renoprotection of dapagliflozin in human renal proximal tubular
cells via the inhibition of the high mobility group box 1-receptor
for advanced glycation end products-nuclear factor-kappaB signaling
pathway. Mol Med Rep. 18:3625–3630. 2018.PubMed/NCBI
|
|
41
|
Oraby MA, El-Yamany MF, Safar MM, Assaf N
and Ghoneim HA: Dapagliflozin attenuates early markers of diabetic
nephropathy in fructose-streptozotocin-induced diabetes in rats.
Biomed Pharmacother. 109:910–920. 2019. View Article : Google Scholar
|
|
42
|
Dixon SJ and Stockwell BR: The role of
iron and reactive oxygen species in cell death. Nat Chem Biol.
10:9–17. 2014. View Article : Google Scholar
|
|
43
|
Xiao C, Fu X, Wang Y, Liu H, Jiang Y, Zhao
Z and You F: Transferrin receptor regulates malignancies and the
stemness of hepatocellular carcinoma-derived cancer stem-like cells
by affecting iron accumulation. PLoS One. 15:e02438122020.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zheng J and Conrad M: The metabolic
underpinnings of ferroptosis. Cell Metab. 32:920–937. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Sha W, Hu F, Xi Y, Chu Y and Bu S:
Mechanism of ferroptosis and its role in type 2 diabetes mellitus.
J Diabetes Res. 2021:99996122021. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Dodson M, Castro-Portuguez R and Zhang DD:
NRF2 plays a critical role in mitigating lipid peroxidation and
ferroptosis. Redox Biol. 23:1011072019. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Yang WS, Kim KJ, Gaschler MM, Patel M,
Shchepinov MS and Stockwell BR: Peroxidation of polyunsaturated
fatty acids by lipoxygenases drives ferroptosis. Proc Natl Acad Sci
USA. 113:E4966–E4975. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Hao L, Mi J, Song L, Guo Y, Li Y, Yin Y
and Zhang C: SLC40A1 mediates ferroptosis and cognitive dysfunction
in type 1 diabetes. Neuroscience. 463:216–226. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Matsumoto M, Sasaki N, Tsujino T, Akahori
H, Naito Y and Masuyama T: Iron restriction prevents diabetic
nephropathy in Otsuka Long-Evans tokushima fatty rat. Ren Fail.
35:1156–1162. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Wang N, Ma H, Li J, Meng C, Zou J, Wang H,
Liu K, Liu M, Xiao X, Zhang H and Wang K: HSF1 functions as a key
defender against palmitic acid-induced ferroptosis in
cardiomyocytes. J Mol Cell Cardiol. 150:65–76. 2021. View Article : Google Scholar
|
|
51
|
Gao HQ, Xu SD, Ren CW, Yang S, Liu CL,
Zhen J, Liu YM, Zhu JM, Huang LJ and Sun LZ: Analysis of
perioperative outcome and long-term survival rate of thoracic
endovascular aortic repair in uncomplicated type B dissection:
Single-centre experience with 751 patients. Eur J Cardiothorac
Surg. 56:1090–1096. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Feng X, Wang S, Sun Z, Dong H, Yu H, Huang
M and Gao X: Ferroptosis enhanced diabetic renal tubular injury via
HIF-1alpha/HO-1 Pathway in db/db Mice. Front Endocrinol (Lausanne).
12:6263902021. View Article : Google Scholar
|
|
53
|
Chen W, Zhang Y, Wang Z, Tan M, Lin J,
Qian X, Li H and Jiang T: Dapagliflozin alleviates myocardial
ischemia/reperfusion injury by reducing ferroptosis via MAPK
signaling inhibition. Front Pharmacol. 14:10782052023. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Pennig J, Scherrer P, Gissler MC,
Anto-Michel N, Hoppe N, Funer L, Härdtner C, Stachon P, Wolf D,
Hilgendorf I, et al: Glucose lowering by SGLT2-inhibitor
empagliflozin accelerates atherosclerosis regression in
hyperglycemic STZ-diabetic mice. Sci Rep. 9:179372019. View Article : Google Scholar :
|
|
55
|
Ema C, Iwakura T, Tsuji N, Nakayama Y,
Tsuchida M, Kitamura A, Katahashi N, Ishigaki S, Isobe S, Fujikura
T, et al: Teneligliptin and empagliflozin attenuate
ferroptosis-mediated acute tubular injury. Nephrol Dial Transplant.
4:750–765. 2025.
|
|
56
|
Ngo V and Duennwald ML: Nrf2 and oxidative
stress: A general overview of mechanisms and implications in human
disease. Antioxidants (Basel). 11:23452020. View Article : Google Scholar
|
|
57
|
Kobayashi A, Kang MI, Watai Y, Tong KI,
Shibata T, Uchida K and Yamamoto M: Oxidative and electrophilic
stresses activate Nrf2 through inhibition of ubiquitination
activity of Keap1. Mol Cell Biol. 26:221–229. 2006. View Article : Google Scholar :
|
|
58
|
Osburn WO and Kensler TW: Nrf2 signaling:
An adaptive response pathway for protection against environmental
toxic insults. Mutat Res. 659:31–39. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Na HK and Surh YJ: Oncogenic potential of
Nrf2 and its principal target protein heme oxygenase-1. Free Radic
Biol Med. 67:353–365. 2014. View Article : Google Scholar
|
|
60
|
Zhang R, Xu M, Wang Y, Xie F, Zhang G and
Qin X: Nrf2-a promising therapeutic target for defensing against
oxidative stress in stroke. Mol Neurobiol. 54:6006–6017. 2017.
View Article : Google Scholar
|
|
61
|
de Haan JB: Nrf2 activators as attractive
therapeutics for diabetic nephropathy. Diabetes. 60:2683–2684.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Jiang T, Huang Z, Lin Y, Zhang Z, Fang D
and Zhang DD: The protective role of Nrf2 in streptozotocin-induced
diabetic nephropathy. Diabetes. 59:850–860. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Wang H, Yu X, Liu D, Qiao Y, Huo J, Pan S,
Zhou L, Wang R, Feng Q and Liu Z: VDR activation attenuates renal
tubular epithelial cell ferroptosis by regulating Nrf2/HO-1
signaling pathway in diabetic nephropathy. Adv Sci (Weinh).
11:e23055632023. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Kong W, Liu X, Zhu H, Zheng S, Yin G, Yu
P, Shan Y, Ma S, Ying R and Jin H: Tremella fuciformis
polysaccharides induce ferroptosis in Epstein-Barr virus-associated
gastric cancer by inactivating NRF2/HO-1 signaling. Aging (Albany
NY). 16:1767–1780. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Qian Z, Zhang Q, Li P, Li Y, Zhang Y, Li
R, Zhao T, Xia M, Chen Y and Hong X: A disintegrin and
metalloproteinase-8 protects against Erastin-Induced neuronal
ferroptosis via activating Nrf2/HO-1/FTH1 signaling pathway. Mol
Neurobiol. 61:3490–3502. 2024. View Article : Google Scholar
|
|
66
|
Xiang S, Zhao L, Tang C, Ling L, Xie C,
Shi Y, Liu W, Li X and Cao Y: Icariin inhibits osteoblast
ferroptosis via Nrf2/HO-1 signaling and enhances healing of
osteoporotic fractures. Eur J Pharmacol. 965:1762442023. View Article : Google Scholar
|
|
67
|
Yang R, Gao W, Wang Z, Jian H, Peng L, Yu
X, Xue P, Peng W, Li K and Zeng P: Polyphyllin I induced
ferroptosis to suppress the progression of hepatocellular carcinoma
through activation of the mitochondrial dysfunction via
Nrf2/HO-1/GPX4 axis. Phytomedicine. 122:1551352024. View Article : Google Scholar
|
